Related by context. All words. (Click for frequent words.) 79 oral bioavailability 72 pharmacodynamic profile 71 pharmacodynamic properties 71 pharmacokinetic profiles 71 pharmacokinetic profile 71 biodistribution 71 favorable pharmacokinetic 70 tolerability profile 68 tolerability profiles 68 ENMD # 68 anti leukemic 67 Zysolin TM 67 orally bioavailable 67 tolerability 66 pharmacokinetic interactions 66 neuroprotective properties 66 favorable pharmacokinetic profile 66 vivo potency 66 oral prodrug 65 CDK inhibitor 65 #ME# 65 bioavailability 65 antiviral efficacy 65 antiviral activity 65 VDAs 65 effector functions 65 pharmacokinetics 65 CCX# 65 PI3K inhibitor 65 Tyrima 65 antitumor activity 65 immunogenicity 65 Anticalins ® 65 anticancer activity 65 Sym# 65 systemic absorption 65 CaPre TM 65 MEK inhibitors 65 Xanafide 65 receptor inhibitor 64 Preclinical studies suggest 64 pharmacokinetic characteristics 64 pharmacodynamic PD 64 antitumor efficacy 64 effector function 64 Interferon alpha 64 LT NS# 64 nucleoside analogs 64 cytotoxicity 64 pharmacokinetic 64 cleavable linker 64 CANCIDAS 64 delafloxacin 64 tumorigenicity 64 mTOR inhibitors 63 dosing regimens 63 PRTX 63 Anticalins R 63 HCV protease inhibitors 63 anti amnesic 63 potency selectivity 63 cannabinor 63 LEP ETU 63 ESBA# 63 Exelixis compounds 63 Anticalins 63 xenograft models 63 vascular disrupting agents 63 plasma kallikrein inhibitor 63 adipiplon 63 EZN 63 efficacy 63 pharmacokinetic PK profile 63 pharmacokinetics PK 63 ganetespib 63 active moiety 63 orally dosed 63 antiviral potency 63 PDE4 inhibitors 63 DXL# 63 analgesic efficacy 63 Vidofludimus 63 histone deacetylase inhibitor 63 urocortin 2 62 vivo efficacy 62 caspofungin 62 TELINTRA 62 active metabolite 62 erlotinib Tarceva ® 62 pharmacokinetic PK 62 nucleoside analog 62 Anidulafungin 62 immunomodulators 62 posaconazole 62 Gleevec resistant 62 efficacy tolerability 62 dosing frequency 62 antisense compounds 62 JAK inhibitor 62 Hsp# inhibitors 62 pharmacokinetic parameters 62 antitumor effect 62 Oral NKTR 62 PDE4 inhibitor 62 ocular formulation 62 NEUGENE antisense 62 GHRH 62 demonstrated antitumor activity 62 vidofludimus 62 BAL# [002] 62 liposomal formulation 62 HGS ETR2 62 pharmacodynamic profiles 62 radiation sensitizer 62 interferon alfa 2b 62 Darinaparsin 62 mecamylamine 62 triphendiol 62 preclinically 62 Azedra 62 safety tolerability pharmacokinetic 62 systemically administered 62 pomalidomide 62 echinocandin 62 highly immunogenic 62 enzyme inhibitor 62 DAVANAT 62 plasma pharmacokinetics 62 ISIS # 62 polymerase inhibitor 62 Seliciclib 62 proteasome inhibitors 62 selective antagonist 62 nanomolar 62 S/GSK# 62 polymerase inhibitors 62 cytotoxic 62 tigecycline 62 immunomodulatory 62 imatinib resistant 61 interferon IFN 61 pharmacodynamics 61 TG# [003] 61 chlorambucil 61 vitro cytotoxicity 61 pan HDAC inhibitor 61 administered subcutaneously 61 riociguat 61 preclinical efficacy 61 RDEA# 61 panitumumab Vectibix 61 PRT# 61 pharmacodynamic parameters 61 chemotherapeutic drug 61 REP# 61 antitumor effects 61 Symadex 61 cytoprotective 61 dose proportional pharmacokinetics 61 oritavancin 61 PEG SN# 61 combinability 61 erythropoietic 61 bactericidal activity 61 mapatumumab 61 Archexin 61 chemopreventive agent 61 DACH platinum 61 small molecule activators 61 ritonavir boosted 61 2 methoxyestradiol 61 tasimelteon 61 docetaxel Taxotere ® 61 XmAb# 61 factor Xa inhibitor 61 antithrombotic 61 cytotoxic agents 61 selective inhibition 61 immunomodulatory therapy 61 JAK2 inhibitors 61 galiximab 61 partial agonist 61 cytochrome P# #A# 61 pro angiogenic 61 pharmacodynamics PD 61 bronchodilation 61 rHuPH# 61 antitumor 61 retapamulin 61 GLYX 61 cMET 61 PEGylated 61 NGX# 61 antiangiogenic agents 61 favorable tolerability 61 indibulin 61 YONDELIS 61 immune modulating 61 Traficet EN 61 calcitonin 61 refractory gout 61 NS#/#A protease 61 anti CD3 61 antiangiogenic activity 61 NEUGENE 61 teriflunomide 61 Preclinical studies 61 mertansine 61 potent antiviral 61 intravenous cyclophosphamide 61 Dasatinib 61 subcutaneously injected 61 alvespimycin 61 BAY #-# 61 novel peptide 61 K ras mutations 61 maximally tolerated dose 61 milatuzumab 61 Pharmacokinetics PK 60 pharmacokinetics pharmacodynamics 60 Aurora kinase 60 GnRH antagonist 60 CD# antibody [001] 60 JAK inhibitors 60 cetuximab Erbitux ® 60 nucleotide analogs 60 CA4P 60 Nanobody ® 60 imatinib Gleevec ® 60 davunetide intranasal AL 60 tyrosine kinase inhibitor TKI 60 transgene expression 60 generation purine nucleoside 60 oxazolidinone 60 CYC# 60 decitabine 60 5 HT2C receptor 60 macrolide antibiotic 60 proteasome inhibitor 60 Omacetaxine mepesuccinate 60 uric acid lowering 60 PXD# 60 subcutaneously administered 60 nanomolar range 60 dosage regimens 60 HGS ETR1 mapatumumab 60 tezampanel NGX# 60 Tolerability 60 Tasimelteon 60 sorafenib Nexavar 60 protease inhibitor PI 60 idraparinux 60 micafungin 60 selective modulator 60 Apoptone 60 dexamethasone Decadron 60 multitargeted 60 TNF inhibitor 60 NanoEmulsion 60 immunomodulator 60 oral gallium 60 microglial activation 60 idarubicin 60 RGB # 60 GelSite R polymer 60 AAG geldanamycin analog 60 FK# 60 pegylated interferons 60 IFN beta 60 fluvastatin 60 ancrod 60 oral dosing 60 non nucleoside 60 Telintra 60 TRIOLEX 60 NNRTIs 60 Vorinostat 60 receptor tyrosine kinase inhibitor 60 immunomodulation 60 ceftazidime 60 synthase TS 60 tipifarnib 60 anti fibrotic 60 HCV protease 60 anidulafungin 60 IL #p# 60 antifibrotic 60 imatinib Gleevec 60 daunorubicin 60 linear pharmacokinetics 60 NMDA antagonists 60 AKT inhibitor 60 microtubule inhibitor 60 pegylated 60 DU #b 60 glycopyrrolate 60 melphalan prednisone 60 fulvestrant 60 radezolid 60 TriRima 60 antigenicity 60 KL4 surfactant 60 vorinostat 60 Panzem 60 FVIIa 60 NexACT 60 tanespimycin 60 CINOD 60 CG# [003] 60 HGS# 60 rFIXFc 60 torezolid phosphate 60 Bezielle 60 metaglidasen 60 bendamustine 60 CLORETAZINE TM VNP#M 60 preclinical studies 60 isatoribine 60 immune stimulatory 60 CBLC# 60 vascular disrupting 60 plasmin 60 Hsp# inhibitor 60 interferon lambda 60 visilizumab 60 Alocrest 60 hA# 60 potentially hepatotoxic 60 solithromycin 59 ularitide 59 anti proliferative 59 somatostatin analogue 59 potent antitumor activity 59 humanized anti 59 Factor VIIa 59 TRV# [001] 59 imatinib therapy 59 SERMs 59 axitinib 59 CEQ# 59 inhibitory effects 59 nonclinical studies 59 epigenetic therapies 59 antiandrogens 59 immunological responses 59 cyclosporin 59 R#/MEM # 59 muscarinic 59 amphotericin B 59 R roscovitine 59 oral antidiabetic 59 pharmacodynamic effects 59 Tarceva TM 59 Iloperidone 59 dasatinib Sprycel 59 RLY# 59 CYP3A 59 immunomodulating 59 cardiac toxicity 59 Orally administered 59 Valortim ® 59 LY# [003] 59 OMP #M# 59 MTP inhibitor 59 Triolex 59 R baclofen 59 Carfilzomib 59 temsirolimus 59 EGFR targeting 59 intravenous dosing 59 Nanobody 59 INCB# [003] 59 mycophenolate mofetil 59 Th2 cytokines 59 INCB# [001] 59 #D#C# 59 menadione 59 PTP 1B 59 AQ4N 59 nanomolar potency 59 RH1 59 CYT# 59 dose proportionality 59 NXL# 59 teduglutide 59 pharmacodynamic markers 59 Cleviprex TM clevidipine 59 immune modulatory 59 Tamibarotene 59 topical formulations 59 p# biomarkers 59 lapatinib Tykerb 59 depsipeptide 59 IMC A# 59 humanized monoclonal 59 anticancer agent 59 oral antiviral 59 target enzyme thymidylate 59 protein kinase inhibitor 59 amrubicin 59 INCB# [002] 59 mGluR5 NAM 59 fibrinolytic 59 pathophysiological effects 59 thalidomide Thalomid 59 Tß4 59 HSP# inhibitor 59 Cloretazine R VNP#M 59 Hyphanox 59 selective kinase inhibitor 59 #HT#A 59 apremilast 59 Targretin 59 nanoviricide drug 59 ARIKACE ™ 59 Anticalin R 59 renal toxicity 59 prokinetic 59 Hsp# inhibition 59 HuLuc# 59 bexarotene 59 exendin 4 59 novel anticancer 59 Ophena TM 59 antitumoral 59 betamethasone dipropionate 59 bevacizumab Avastin ® 59 docetaxel chemotherapy 59 nanopharmaceutical 59 BAL# [001] 59 ritonavir boosting 59 Zoraxel TM 59 Genz # 59 Aplidin 59 Panzem R 59 thrombogenic 59 anti angiogenic 59 pharmacodynamic 59 HCV replication 59 HIF PH inhibitors 59 p# inhibitors 59 SGS# 59 Onconase 59 urate lowering 59 Vaxfectin R 59 Pimavanserin 59 PSN# [002] 59 monoclonal 59 selective agonist 59 TKM ApoB 59 tezampanel 59 conventional DMARDs 59 inhibitor RG# 59 pro apoptotic 59 BRAF inhibitor 59 fosbretabulin 59 lomitapide 59 intranasal delivery 59 p# activation 59 ADP receptor antagonist 59 busulfan 59 Voreloxin 59 Akt inhibitor 59 cilengitide 59 epothilone 59 chemotherapeutics 59 orally administered inhibitor 59 Panzem R NCD 59 huC# DM4 59 alemtuzumab MS 59 azacitidine 59 latanoprost 59 bronchodilatory 59 immunomodulatory effects 59 Dapagliflozin 59 gemcitabine cisplatin 59 statin simvastatin 59 BYETTA exenatide injection 59 peptide conjugated 59 ruxolitinib 59 Relivar 59 huN# DM1 59 echinocandins 59 active comparator 59 lenalidomide dexamethasone 59 IFN α 59 ON #.Na 59 PEGylated interferon 59 sitaxsentan 59 entinostat 59 azacytidine 59 HuMax EGFr 59 nilotinib Tasigna ® 59 DMARDS 59 TNF α 59 SCH # 59 isotypes 59 caspase inhibitors 59 NOX E# 59 liposomal amphotericin B 59 tolerability pharmacokinetics 59 TELCYTA 59 HQK 59 Guanilib 59 binding affinity 59 ciclesonide 59 Anticalin ® 59 relapsed MM 58 HuMax CD# 58 trabectedin 58 Azacitidine 58 non selective NMDA 58 TPI ASM8 58 CYT# potent vascular disrupting 58 synthetic siRNA 58 biologic therapeutics 58 EndoTAG TM -1 58 5 HT1A receptor 58 immunogenic 58 paricalcitol 58 forodesine 58 fumagillin nanoparticles 58 Etoposide 58 mu opioid receptor antagonist 58 Cloretazine 58 Hematologic toxicity 58 antiproliferative effects 58 USL# 58 MGd 58 neurotoxicity 58 CIMZIA ™ 58 replicon 58 LY# [002] 58 prodrugs 58 synthetic retinoid 58 intracellular uptake 58 paclitaxel Taxol 58 GAP #B# 58 antidiabetic 58 rBChE 58 CCR9 antagonist 58 topical formulation 58 Nanobodies 58 brain penetrant 58 ATL/TV# 58 vinca alkaloid 58 Teriflunomide 58 Posiphen 58 GSK3B 58 nucleosides 58 diabetic neuropathic pain 58 rHuEPO 58 subcutaneous formulation 58 antifolates 58 SRT# [003] 58 oral JAK1 58 systemic bioavailability 58 vascular disrupting agent 58 AZT zidovudine Retrovir 58 CD# expressing 58 #beta estradiol 58 mTOR inhibitor 58 VELCADE melphalan 58 IFN alpha 58 dosed orally 58 DCCR 58 CD# monoclonal antibody 58 MYDICAR ® 58 glycosylation profile 58 Vaxfectin TM 58 CRLX# 58 FOSRENOL ® 58 vinorelbine 58 Belerofon 58 MAP# 58 IMiDs 58 Vidaza azacitidine 58 uricase 58 bovine thrombin 58 Epothilones 58 iroxanadine 58 LSI #P 58 Prodarsan ® 58 phase IIb clinical 58 flavopiridol 58 virus HCV protease inhibitor 58 antiarrhythmic 58 metastatic RCC 58 pharmacokinetic equivalence 58 enzyme inhibitors 58 PLX cells 58 Neulasta ® 58 carbohydrate polymer 58 EDEMA3 trial 58 olmesartan 58 PI3K inhibitors 58 salmeterol fluticasone 58 pyrimidine 58 HGS ETR1 58 fosamprenavir 58 Androxal TM 58 Laquinimod 58 cellular uptake 58 Mipomersen 58 CorVue ™ 58 nitric oxide donating 58 NOD SCID mice 58 PI3K/Akt pathway inhibitor 58 CTA# 58 cidofovir 58 TBC# 58 racemic 58 SAR# [002] 58 Hedgehog inhibitor 58 deferiprone 58 TOCOSOL Camptothecin 58 dacarbazine 58 viral kinetics 58 latrepirdine 58 osteogenic 58 TLR8 58 azole 58 tricyclic 58 nucleoside analogues 58 gemcitabine Gemzar 58 novel VDA molecule 58 hemagglutination inhibition HAI 58 IFN Beta 58 EGFR HER2 58 tiotropium bromide 58 insulin sensitizing 58 TLR9 agonist 58 Kinoid 58 intravenously administered 58 PC# cells 58 VA# [002] 58 molecularly targeted 58 novel histone deacetylase 58 VEGF inhibitors 58 MAb 58 pharmacologically active isomer 58 Zavesca R 58 AGHD 58 Annexin V 58 Serdaxin 58 ApoA1 58 HCV replicon 58 RhuDex ® 58 weekly subcutaneous injections 58 fluconazole resistant 58 fluticasone furoate 58 multikinase inhibitor 58 OXIGON TM 58 pharmacokinetic PK study 58 DepoVax ™ 58 ulimorelin 58 safety tolerability pharmacokinetics 58 Azedra TM 58 brostallicin 58 XL# XL# 58 ZYBRESTAT 58 SNRI 58 cytostatic 58 FUSILEV enhances 58 itraconazole Sporanox 58 nanoviricide 58 Phase Ib study 58 peptidic 58 BioVant 58 IAP inhibitor 58 partial agonists 58 amprenavir 58 lupus nephritis 58 adenoviral 58 OMNARIS HFA 58 XL# XL# XL# XL# 58 reactogenicity 58 novel orally bioavailable 58 Solulin 58 nucleoside 58 granisetron 58 parathyroid hormone PTH 58 potent inhibition 58 selective inverse agonist 58 factor TNF 58 tumor necrosis 58 ibudilast 58 bleomycin 58 metastatic renal cell carcinoma 58 investigational hepatitis C 58 membrane permeability 58 NAGS deficiency 58 non nucleoside HCV 58 ritonavir boosted protease inhibitor 58 vivo 58 pharmacologic 58 ara C 58 antiangiogenic 58 antiproliferative activity 58 small molecule defensin 58 DuraSite 58 neointimal proliferation 58 racemic mixture 58 obatoclax 58 MyVax R 58 goserelin 58 Src inhibitors 58 IgG1 58 plasma concentrations 58 lipid particles 58 prucalopride 58 sodium glucose cotransporter 58 microtubule targeting 58 Navelbine ® 58 Cannabinor 58 antibody fragment 58 GRN#L 58 Factor IX 58 DermaVir Patch 58 kinase inhibition 58 ZK EPO 58 MAGE A3 ASCI 58 pramlintide metreleptin combination 58 ZYBRESTAT fosbretabulin 58 cyclophilin inhibitor 58 IFN ß 58 noninfectious uveitis 58 capsule formulation 58 selective androgen receptor modulator 58 FluCide 58 Akt activation 58 immunofluorescence staining 58 TNFa 58 selegiline 58 investigational humanized monoclonal antibody 58 low dose ritonavir 58 antisense drug 58 alkylating agent 58 BMS# 58 triphosphate 58 PEGPH# 58 prostanoid 58 anticancer therapy 58 thymalfasin 58 coadministration 58 HuMax CD4 57 VEGF receptor 57 miconazole 57 therapeutic efficacy 57 TH# [003] 57 intranasal formulation 57 non steroidal 57 Enzastaurin 57 antimitotic 57 potent antiproliferative 57 substrates inhibitors 57 5 FU leucovorin 57 dose regimens 57 poloxamer 57 somatostatin 57 calcineurin inhibitors 57 GPx 57 HIF PHI 57 antidiabetic drugs 57 antiangiogenic agent 57 histone deacetylase HDAC 57 gastrointestinal motility 57 dose cohorts 57 lisdexamfetamine dimesylate 57 Telmisartan 57 KB# [002] 57 binding affinities 57 TNFalpha 57 oral formulation 57 CINTREDEKIN BESUDOTOX 57 immunomodulatory properties 57 ALN TTR# 57 bioactivity 57 XP# Transported Prodrug 57 anti angiogenic agents 57 immunostimulatory 57 trastuzumab Herceptin ® 57 SARMs 57 anti EGFR antibody 57 ZOLINZA 57 Smac mimetic 57 Abeta# 57 hepatoma 57 enzastaurin 57 retinoid 57 vitro antiviral 57 antiapoptotic 57 Darusentan 57 teriparatide 57 5 FU 57 investigational protease inhibitor 57 nephrotoxicity 57 Maribavir 57 CoFactor 57 small molecule tyrosine 57 UsiRNAs 57 S1P antibody 57 hepatotoxic 57 Amrubicin 57 bactericidal 57 CYP #A# 57 AEG# 57 myelofibrosis polycythemia vera 57 pegylated liposomal doxorubicin 57 plasma kallikrein 57 beclomethasone dipropionate 57 PS# [001] 57 evaluating tivozanib 57 isoproterenol 57 Doxil ® 57 BioSilicon 57 sunitinib Sutent ® 57 nanoviricides 57 pharmacodynamic endpoints 57 paclitaxel Taxol ® 57 L asparaginase 57 TLR agonists 57 adrenal suppression 57 pharmacologically 57 elotuzumab 57 CTAP# Capsules 57 antisense inhibition 57 xanthine oxidase inhibitor 57 peripheral blood mononuclear 57 dasatinib 57 sd rxRNA 57 nucleoside reverse transcriptase inhibitor 57 EOquin 57 adecatumumab 57 C1 INH 57 TLR8 agonist 57 convenient dosing regimens 57 investigational pan BCR 57 antisense inhibitors 57 orally bioavailable mimics 57 sorafenib Nexavar ® 57 OXi# 57 tumorigenic 57 CORT # 57 neurotrophic 57 mitomycin 57 omega interferon 57 lopinavir 57 steroid dexamethasone 57 zileuton 57 SERCA2a 57 GMX# 57 osteoinductive 57 NPD1 57 Pegasys ® 57 lipid lowering therapies 57 Chrysalin 57 PEGylated interferon beta 1a 57 deacetylase inhibitors 57 RSD# 57 small molecule thrombopoietin 57 pertuzumab 57 DDP# 57 KSP inhibitor 57 subcutaneous SC 57 synthetic peptide 57 therapeutic monoclonal antibody 57 5 HT4 receptor 57 elacytarabine 57 direct thrombin inhibitors 57 CCR5 antagonist 57 MAXY G# 57 Vidaza ® 57 Pazopanib 57 GLP toxicology studies 57 antiarrhythmic agent 57 EGFR antibodies 57 agomelatine 57 bosentan 57 Luteinizing Hormone Releasing Hormone 57 Zoraxel 57 peptidomimetic 57 anti emetic therapy 57 Solazed TM 57 polymyxin B 57 tryptase 57 integrase inhibitor 57 Marqibo 57 neuroprotective effects 57 chemotherapy induced neutropenia 57 Losartan 57 alagebrium 57 Plicera 57 topoisomerase 57 rifalazil 57 platelet inhibitor 57 molecular biomarkers 57 cytotoxic effects 57 adapalene 57 NMDA antagonist 57 inhibitory activity 57 AEGR 57 targeted antifolate 57 Cyclosporine 57 hepatic fibrosis 57 XL# inhibits 57 Fludara 57 PCK# 57 renin inhibitor 57 induce apoptosis 57 cobiprostone 57 overlapping toxicities 57 PEGylated Fab fragment 57 belinostat 57 Radezolid 57 Blinatumomab 57 nucleotide analog 57 Aurora Kinase 57 IMGN# 57 epothilones 57 benzimidazole 57 Golimumab 57 subtype selective 57 Aliskiren 57 vWF 57 humanized monoclonal antibodies 57 immunostimulatory effects 57 risperidone Risperdal 57 acromegalic patients 57 beta interferons 57 serum LDL cholesterol 57 rNAPc2 57 LHRH antagonists 57 Flt3 57 Aclidinium 57 HMG CoA reductase inhibitor 57 MGCD# [001] 57 ADME properties 57 micronuclei 57 torezolid 57 dihydrofolate reductase 57 PSMA ADC 57 anti CD# antibodies 57 antifungal drugs 57 Pharmacokinetic PK 57 telbivudine 57 gemifloxacin 57 airway hyper responsiveness 57 oxidative stress inducer 57 antineoplastic 57 DB# [003] 57 Valdoxan 57 hyperoxaluria 57 LAB CGRP 57 anti inflammatory cytokine 57 fibrotic disease 57 CYP#A# substrates 57 candesartan cilexetil 57 Capecitabine 57 Fluconazole 57 catalytic antioxidant 57 serum concentrations 57 DiLA2 57 omecamtiv mecarbil 57 liposome formulation 57 alefacept 57 peptide antigens 57 iobenguane 57 salmon calcitonin 57 Valproic acid 57 inhibit EGFR 57 alpha interferon 57 pyrimidines 57 factor G CSF 57 Dalbavancin 57 immune modulator 57 MoxDuo ® IR 57 fluoroquinolone antibiotic 57 Safinamide 57 selectively inhibits 57 long acting muscarinic 57 geldanamycin 57 Pharmacokinetic 57 dosing regimen 57 paclitaxel eluting stents 57 selective adenosine 57 CGEN # 57 cardiotoxic 57 Visipaque 57 imetelstat 57 2 methoxyestradiol #ME# 57 heparanase 57 systemic toxicity 57 serum PTH 57 indinavir 57 TNF antagonist 57 fluconazole 57 Zolinza 57 sigma receptors